mRNA Structural Constraints on EBNA1 Synthesis Impact on In Vivo Antigen Presentation and Early Priming of CD8+ T Cells

PLoS Pathogens

Volumn 10, Issue 10, 2014, Pages

  Tellam, Judy T ^a   Zhong, Jie ^a   Lekieffre, Lea ^a   Bhat, Purnima ^b   Martinez, Michelle ^a   Croft, Nathan P ^c   Kaplan, Warren ^d   Tellam, Ross L ^e   Khanna, Rajiv ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b The Australian National University   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e CSIRO   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4', 6 DIAMIDINO 2 PHENYLINDOLE; ADENOVIRUS VECTOR; ANTISENSE OLIGONUCLEOTIDE; BETA GALACTOSIDASE; CD27 ANTIGEN; CD69 ANTIGEN; EPITOPE; EPSTEIN BARR VIRUS ANTIGEN 1; FLUORESCEIN ISOTHIOCYANATE; GAMMA INTERFERON; GLYCOPROTEIN P 15095; GREEN FLUORESCENT PROTEIN; GUANINE QUADRUPLEX; HERMES ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR BETA; L SELECTIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA; T BOX TRANSCRIPTION FACTOR; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR T BET; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN DETECTION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CD8+ T LYMPHOCYTE; CELL PERMEABILIZATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION ASSAY; GENE TRANSLOCATION; HEK293 CELL LINE; HUMAN; HUMAN CELL; HYBRIDOMA CELL CULTURE; IMMUNIZATION; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PLAQUE FORMING CELL ASSAY; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN SYNTHESIS REGULATION; RNA SEQUENCE; RNA TRANSLATION; T LYMPHOCYTE ACTIVATION; TRANSLATION REGULATION; VIRUS CELL INTERACTION;

EID: 84908334838     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004423     Document Type: Article

References (54)

1. Doherty PC, Christensen JP, Belz GT, Stevenson PG, Sangster MY, (2001) Dissecting the host response to a gamma-herpesvirus. Philosophical transactions of the Royal Society of London Series B, Biological sciences 356: 581–593.
2. Tellam J, Connolly G, Green KJ, Miles JJ, Moss DJ, et al. (2004) Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1. J Exp Med 199: 1421–1431.
3. Voo KS, Fu T, Wang HY, Tellam J, Heslop HE, et al. (2004) Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes. J Exp Med 199: 459–470.
4. Yewdell JW, (2005) Serendipity strikes twice: the discovery and rediscovery of defective ribosomal products (DRiPS). Cell Mol Biol (Noisy-le-grand) 51: 635–641.
5. Yewdell JW, Anton LC, Bennink JR, (1996) Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? J Immunol 157: 1823–1826.
6. Yin Y, Manoury B, Fahraeus R, (2003) Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science 301: 1371–1374.
7. Ryan AA, Nambiar JK, Wozniak TM, Roediger B, Shklovskaya E, et al. (2009) Antigen load governs the differential priming of CD8 T cells in response to the bacille Calmette Guerin vaccine or Mycobacterium tuberculosis infection. J Immunol 182: 7172–7177.
8. Russell MS, Iskandar M, Mykytczuk OL, Nash JH, Krishnan L, et al. (2007) A reduced antigen load in vivo, rather than weak inflammation, causes a substantial delay in CD8+ T cell priming against Mycobacterium bovis (bacillus Calmette-Guerin). J Immunol 179: 211–220.
9. Zheng H, Jin B, Henrickson SE, Perelson AS, von Andrian UH, et al. (2008) How antigen quantity and quality determine T-cell decisions in lymphoid tissue. Mol Cell Biol 28: 4040–4051.
10. Khanna R, Burrows SR, Moss DJ, (1995) Immune regulation in Epstein-Barr virus-associated diseases. Microbiol Rev 59: 387–405.
11. Munz C, (2004) Epstein-barr virus nuclear antigen 1: from immunologically invisible to a promising T cell target. J Exp Med 199: 1301–1304.
12. Levitskaya J, Coram M, Levitsky V, Imreh S, Steigerwald-Mullen PM, et al. (1995) Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375: 685–688.
13. Levitskaya J, Sharipo A, Leonchiks A, Ciechanover A, Masucci MG, (1997) Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci U S A 94: 12616–12621.
14. Tellam J, Sherritt M, Thomson S, Tellam R, Moss DJ, et al. (2001) Targeting of EBNA1 for rapid intracellular degradation overrides the inhibitory effects of the Gly-Ala repeat domain and restores CD8+ T cell recognition. J Biol Chem 276: 33353–33360.
15. Apcher S, Daskalogianni C, Manoury B, Fahraeus R, (2010) Epstein Barr virus-encoded EBNA1 interference with MHC class I antigen presentation reveals a close correlation between mRNA translation initiation and antigen presentation. PLoS Pathog 6: e1001151.
16. Mackay LK, Long HM, Brooks JM, Taylor GS, Leung CS, et al. (2009) T cell detection of a B-cell tropic virus infection: newly-synthesised versus mature viral proteins as antigen sources for CD4 and CD8 epitope display. PLoS pathogens 5: e1000699.
17. Tellam J, Fogg MH, Rist M, Connolly G, Tscharke D, et al. (2007) Influence of translation efficiency of homologous viral proteins on the endogenous presentation of CD8+ T cell epitopes. J Exp Med 204: 525–532.
18. Tellam J, Rist M, Connolly G, Webb N, Fazou C, et al. (2007) Translation efficiency of EBNA1 encoded by lymphocryptoviruses influences endogenous presentation of CD8+ T cell epitopes. Eur J Immunol 37: 328–337.
19. Tellam JT, Lekieffre L, Zhong J, Lynn DJ, Khanna R, (2012) Messenger RNA Sequence Rather than Protein Sequence Determines the Level of Self-synthesis and Antigen Presentation of the EBV-encoded Antigen, EBNA1. PLoS Pathog 8: e1003112.
20. Cardinaud S, Starck SR, Chandra P, Shastri N, (2010) The synthesis of truncated polypeptides for immune surveillance and viral evasion. PLoS One 5: e8692.
21. Apcher S, Komarova A, Daskalogianni C, Yin Y, Malbert-Colas L, et al. (2009) mRNA translation regulation by the Gly-Ala repeat of Epstein-Barr virus nuclear antigen 1. J Virol 83: 1289–1298.
22. Tellam J, Smith C, Rist M, Webb N, Cooper L, et al. (2008) Regulation of protein translation through mRNA structure influences MHC class I loading and T cell recognition. Proc Natl Acad Sci U S A 105: 9319–9324.
23. Murat P, Zhong J, Lekieffre L, Cowieson NP, Clancy JL, et al. (2014) G-quadruplexes regulate Epstein-Barr virus-encoded nuclear antigen 1 mRNA translation. Nature chemical biology 10: 358–364 doi:10.1038/nchembio.1479
24. Cheng LE, Ohlen C, Nelson BH, Greenberg PD, (2002) Enhanced signaling through the IL-2 receptor in CD8+ T cells regulated by antigen recognition results in preferential proliferation and expansion of responding CD8+ T cells rather than promotion of cell death. Proc Natl Acad Sci U S A 99: 3001–3006.
25. Pipkin ME, Sacks JA, Cruz-Guilloty F, Lichtenheld MG, Bevan MJ, et al. (2010) Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity 32: 79–90.
26. Hendriks J, Gravestein LA, Tesselaar K, van Lier RA, Schumacher TN, et al. (2000) CD27 is required for generation and long-term maintenance of T cell immunity. Nature immunology 1: 433–440.
27. van Gisbergen KP, Klarenbeek PL, Kragten NA, Unger PP, Nieuwenhuis MB, et al. (2011) The costimulatory molecule CD27 maintains clonally diverse CD8(+) T cell responses of low antigen affinity to protect against viral variants. Immunity 35: 97–108.
28. Banerjee A, Gordon SM, Intlekofer AM, Paley MA, Mooney EC, et al. (2010) Cutting edge: The transcription factor eomesodermin enables CD8+ T cells to compete for the memory cell niche. J Immunol 185: 4988–4992.
29. Intlekofer AM, Takemoto N, Wherry EJ, Longworth SA, Northrup JT, et al. (2005) Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat Immunol 6: 1236–1244.
30. Joshi NS, Cui W, Chandele A, Lee HK, Urso DR, et al. (2007) Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity 27: 281–295.
31. Pearce EL, Mullen AC, Martins GA, Krawczyk CM, Hutchins AS, et al. (2003) Control of effector CD8+ T cell function by the transcription factor Eomesodermin. Science 302: 1041–1043.
32. Kurts C, Robinson BW, Knolle PA, (2010) Cross-priming in health and disease. Nature reviews Immunology 10: 403–414.
33. Restifo NP, Bacik I, Irvine KR, Yewdell JW, McCabe BJ, et al. (1995) Antigen processing in vivo and the elicitation of primary CTL responses. Journal of immunology 154: 4414–4422.
34. Yewdell JW, Haeryfar SM, (2005) Understanding presentation of viral antigens to CD8+ T cells in vivo: the key to rational vaccine design. Annual review of immunology 23: 651–682.
35. Burrows SR, Moss DJ, Khanna R, (2011) Understanding human T-cell-mediated immunoregulation through herpesviruses. Immunology and cell biology 89: 352–358.
36. Gandhi MK, Khanna R, (2004) Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet InfectDis 4: 725–738.
37. Hilleman MR, (2004) Strategies and mechanisms for host and pathogen survival in acute and persistent viral infections. Proceedings of the National Academy of Sciences of the United States of America 101 Suppl 2: 14560–14566.
38. Khanna R, Burrows SR, (2000) Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. AnnuRevMicrobiol2000;54:19–48 54 19–48 19–48.
39. Khanna R, Moss DJ, Gandhi M, (2005) Applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies. Nature Clinical Practice Oncolcogy 2: 138–149.
40. Apcher S, Fahraeus R, Manoury B, (2004) Epstein-Barr virus: exploiting the immune system by interfering with defective ribosomal products. Microbes Infect 6: 1212–1218.
41. Lee SP, Brooks JM, Al Jarrah H, Thomas WA, Haigh TA, et al. (2004) CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1. The Journal of Experimental Medicine 199: 1409–1420.
42. Bickham K, Goodman K, Paludan C, Nikiforow S, Tsang ML, et al. (2003) Dendritic cells initiate immune control of epstein-barr virus transformation of B lymphocytes in vitro. The Journal of experimental medicine 198: 1653–1663.
43. Lim WH, Kireta S, Russ GR, Coates PT, (2007) Human plasmacytoid dendritic cells regulate immune responses to Epstein-Barr virus (EBV) infection and delay EBV-related mortality in humanized NOD-SCID mice. Blood 109: 1043–1050.
44. Fiola S, Gosselin D, Takada K, Gosselin J, (2010) TLR9 contributes to the recognition of EBV by primary monocytes and plasmacytoid dendritic cells. Journal of immunology 185: 3620–3631.
45. Li L, Liu D, Hutt-Fletcher L, Morgan A, Masucci MG, et al. (2002) Epstein-Barr virus inhibits the development of dendritic cells by promoting apoptosis of their monocyte precursors in the presence of granulocyte macrophage-colony-stimulating factor and interleukin-4. Blood 99: 3725–3734.
46. Severa M, Giacomini E, Gafa V, Anastasiadou E, Rizzo F, et al. (2013) EBV stimulates TLR- and autophagy-dependent pathways and impairs maturation in plasmacytoid dendritic cells: implications for viral immune escape. European journal of immunology 43: 147–158.
47. Subklewe M, Paludan C, Tsang ML, Mahnke K, Steinman RM, et al. (2001) Dendritic cells cross-present latency gene products from Epstein-Barr virus-transformed B cells and expand tumor-reactive CD8(+) killer T cells. The Journal of experimental medicine 193: 405–411.
48. Smith C, Elhassen D, Gras S, Wynn KK, Dasari V, et al. (2012) Endogenous antigen presentation impacts on T-box transcription factor expression and functional maturation of CD8+ T cells. Blood 120: 3237–3245.
49. Yotnda P, Onishi H, Heslop HE, Shayakhmetov D, Lieber A, et al. (2001) Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene therapy 8: 930–937.
50. Karttunen J, Sanderson S, Shastri N, (1992) Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc Natl Acad Sci U S A 89: 6020–6024.
51. Nolan GP, Fiering S, Nicolas JF, Herzenberg LA, (1988) Fluorescence-activated cell analysis and sorting of viable mammalian cells based on beta-D-galactosidase activity after transduction of Escherichia coli lacZ. Proc Natl Acad Sci U S A 85: 2603–2607.
52. Sanderson S, Shastri N, (1994) LacZ inducible, antigen/MHC-specific T cell hybrids. Int Immunol 6: 369–376.
53. Quah BJ, Warren HS, Parish CR, (2007) Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nat Protoc 2: 2049–2056.
54. Zhong J, Rist M, Cooper L, Smith C, Khanna R, (2008) Induction of pluripotent protective immunity following immunisation with a chimeric vaccine against human cytomegalovirus. PLoS One 3: e3256.